We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs.
Our focus and commitment to patients will always remain at the center of everything we do with the aim to add years of life and quality of life of patients across the globe.
Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications.Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.